MX344937B - Composición farmacéutica que combina un anticonvulsivante y un derivado del ácido nicotínico. - Google Patents

Composición farmacéutica que combina un anticonvulsivante y un derivado del ácido nicotínico.

Info

Publication number
MX344937B
MX344937B MX2015003519A MX2015003519A MX344937B MX 344937 B MX344937 B MX 344937B MX 2015003519 A MX2015003519 A MX 2015003519A MX 2015003519 A MX2015003519 A MX 2015003519A MX 344937 B MX344937 B MX 344937B
Authority
MX
Mexico
Prior art keywords
clg
combination
derivate
anticonvulsant
pharmaceutical composition
Prior art date
Application number
MX2015003519A
Other languages
English (en)
Other versions
MX2015003519A (es
Inventor
De Los Ángeles Aguilera Suárez Graciela
Rosaura Juárez Lora Martha
Miguel Gómez Sanchez Carmen
Original Assignee
Farmacéuticos Rayere S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmacéuticos Rayere S A filed Critical Farmacéuticos Rayere S A
Publication of MX2015003519A publication Critical patent/MX2015003519A/es
Publication of MX344937B publication Critical patent/MX344937B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La combinación de gabapentina con clonixinato de lisina (CLG) permite aliviar el dolor neuropático originado tanto por neuropatía diabética como por una lesión al nervio. La combinación CLG produce una sinergia en el efecto antialodínico, cuando la alodinia ha sido generada por un daño mecánico directo al tejido nervioso o cuando se ha producido como consecuencia de una patología diabética. El efecto terapéutico de la combinación CLG es de 3 a 11 veces mayor que el efecto que tiene cada uno de los fármacos por separado. La combinación de CLG es segura ya que no muestra efectos adversos en la actividad motora, ni alteraciones en parámetros neurológicos, tampoco daño a nivel hepático o renal.
MX2015003519A 2014-06-16 2014-06-16 Composición farmacéutica que combina un anticonvulsivante y un derivado del ácido nicotínico. MX344937B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2014/000091 WO2015194926A1 (es) 2014-06-16 2014-06-16 Composición farmacéutica que combina un anticonvulsivante y un derivado del ácido nicotínico

Publications (2)

Publication Number Publication Date
MX2015003519A MX2015003519A (es) 2016-03-15
MX344937B true MX344937B (es) 2017-01-11

Family

ID=54935825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003519A MX344937B (es) 2014-06-16 2014-06-16 Composición farmacéutica que combina un anticonvulsivante y un derivado del ácido nicotínico.

Country Status (8)

Country Link
US (1) US9895362B2 (es)
EP (1) EP3156051B1 (es)
BR (1) BR112016028924A2 (es)
CA (1) CA2951987C (es)
CR (1) CR20160573A (es)
ES (1) ES2709758T3 (es)
MX (1) MX344937B (es)
WO (1) WO2015194926A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053225A1 (en) 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1940380A2 (en) 2005-05-20 2008-07-09 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands
WO2007083985A1 (es) 2006-01-19 2007-07-26 Farmacéuticos Rayere, S.A. Composición farmacéutica sinergística de diclofenaco y clonixinato de lisina
WO2007148950A1 (es) 2006-06-20 2007-12-27 Farmacéuticos Rayere, S.A. Composición farmacéutica sinergística de ketorolaco y clonixinato de lisina
WO2008077599A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS

Also Published As

Publication number Publication date
BR112016028924A2 (pt) 2017-08-22
CA2951987C (en) 2017-10-24
EP3156051A4 (en) 2018-01-03
MX2015003519A (es) 2016-03-15
CR20160573A (es) 2017-03-14
WO2015194926A1 (es) 2015-12-23
US9895362B2 (en) 2018-02-20
CA2951987A1 (en) 2015-12-23
EP3156051A1 (en) 2017-04-19
ES2709758T3 (es) 2019-04-17
EP3156051B1 (en) 2018-11-07
US20170151223A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12017500746A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
IN2015DN03219A (es)
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
EP4039247A3 (en) Sublingual formulation of riluzole
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
NZ728796A (en) Aqueous formulation comprising paracetamol and ibuprofen
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
WO2012106058A3 (en) Animal treatments
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX344937B (es) Composición farmacéutica que combina un anticonvulsivante y un derivado del ácido nicotínico.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
Mandiroglu Sensorimotor peripheral neuropathy: case report
IN2014DE00822A (es)
Ma et al. ELECTROACUPUNCTURE IMPROVES THERAPEUTIC EFFECTS AND DECREASES SIDE EFFECTS OF PAROXETINE FOR MILD OR MODERATE DEPRESSION PATIENTS

Legal Events

Date Code Title Description
FG Grant or registration